Clinical Trial Update: Cetuximab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Update reporting results from a Phase 2 trial of cetuximab in patients with unresectable or metastatic hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Cetuximab (cetuximab)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED